November 28, 2022
All resources
Access a curated library of reports, policy submissions, data insights, and other materials informing Canada’s life sciences ecosystem.
Filter by
November 18, 2022
November 09, 2022
November 09, 2022
Letter to The Honourable Jean-Yves Duclos, P.C., M.P.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
November 09, 2022
November 09, 2022
Letter to The Hon. Chrystia Freeland, P.C., M.P.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
*Cette lettre est disponible en anglais seulement.
November 09, 2022
November 09, 2022
Letter to The Honourable Mary Ng, P.C., M.P.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
*Cette lettre est disponible en anglais seulement.
November 09, 2022
November 09, 2022
Ministerial PMPRB Guideline Letter to The Hon. François-Philippe Champagne, P.C., M.P.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
May 04, 2021
May 04, 2021
Letter to the Honourable Patty Hajdu
IMC requests that the Honourable Patty Hadju suspend the July 1, 2021 implementation of regulatory changes to the PMPRB until the COVID-19 pandemic has abated.
February 14, 2020
February 14, 2020
IMC response to PMPRB draft guidelines
IMC responds to PMPRB draft guidelines released November 21, 2019, stating a balance must be struck between budgetary pressures confronting Canadian governments and the preservation of Canadians’ timely access to life-saving innovative medicines.
